Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 96 (4) , 306-314
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (1051529)
This publication has 36 references indexed in Scilit:
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*Journal of Biological Chemistry, 2007
- COX-2 involvement in breast cancer metastasis to boneOncogene, 2007
- Tumor metastasis: mechanistic insights and clinical challengesNature Medicine, 2006
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Cyclooxygenase 2-derived prostaglandin E 2 regulates the angiogenic switchProceedings of the National Academy of Sciences, 2004
- Role of prostaglandin E 2 -dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progressionProceedings of the National Academy of Sciences, 2003
- Role of prostaglandin E2 receptors in migration of murine and human breast cancer cellsExperimental Cell Research, 2003
- Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesisInternational Journal of Cancer, 2001
- COX-2 is expressed in human pulmonary, colonic, and mammary tumorsCancer, 2000